Guangzhou, China, March 10, 2010 -- China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), primarily a leading distributor and a developer of Western pharmaceuticals, traditional Chinese medicines (“TCM”), and other nutriceuticals, announced today that the the Company has received comments from Nasdaq’s Listing Qualifications Department in response to its application for listing its common stock on the NASDAQ Global Market. China Medicine submitted the application earlier this year, following the board of directors’ approval of the Company’s uplisting.

“With the NASDAQ Global Market listing process now underway, we look forward to reaching this significant milestone in our development as a U.S. publicly-traded company,” stated Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. “As a growing public company, management and the board believe it is in the best interest of our shareholders for the Company to apply for the listing on NASDAQ. Such a move, if approved, can help to broaden the Company’s shareholder base, provide greater trading liquidity and raise the Company’s profile in the investment community.”

Comments from Nasdaq’s Listing Qualifications Department primarily focused on confirmation and supporting details related to factual matters. China Medicine is working expeditiously to submit a response for NASDAQ’s review and believes that it will satisfy all of the listing qualifications associated with its application. The Company's common stock will continue to trade on the OTC Bulletin Board under its current symbol, CHME, until the Company is notified of its acceptance. The Company hopes to receive approval to list its common shares on the Nasdaq Global Market in the near future.

Cautionary Statement

This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, approval to list the Company’s common stock on NASDAQ and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

Guangzhou, China, February 2, 2010 -- China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), primarily a developer, manufacturer and leading distributor in China of Western pharmaceuticals, traditional Chinese medicines (“TCM”), and other nutriceuticals, today announced that it has closed the equity private placement contemplated in its Stock Subscription Agreement dated December 31, 2009 (the “Subscription Agreement”) with One Equity Partners ("OEP"), the global private equity investment arm of JPMorgan Chase & Co.

At closing, China Medicine sold 4,000,000 of the Company’s common shares at $3.00 per share for $12 million in gross proceeds and 1,920,000 of its redeemable convertible preferred shares at $30 per share for $57.6 million in gross proceeds resulting in aggregate net proceeds of $66.5 million. Of the proceeds, $57.6 million has been placed in escrow and will be released to fund additional capital expenditures and acquisition projects subject to approval from OEP and the Company’s board of directors. Each redeemable convertible preferred share is initially convertible into ten common shares.

“The closing of this transaction further augments our ability to execute our growth strategy. With the newly added manufacturing capabilities from the LifeTech Pharmaceuticals Co., Ltd (“LifeTech”) acquisition, we are well on our way to becoming a vertically integrated pharmaceutical company with self-manufactured products sold through our extensive distribution network,” said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation.

The Company also announced that Mr. Ryan Shih, resident partner in OEP’s Hong Kong office, has joined the Company's board of directors.  Prior to joining OEP, Mr. Shih was an investment banker at both Merrill Lynch and Deutsche Bank covering the semiconductor, alternative energy, media, and hardware sectors throughout the Asia-Pacific region. Prior to that, Mr. Shih was an attorney at Skadden Arps. Prior to his legal/financial career, Mr. Shih was a captain in the United States Army. Mr. Shih holds a B.S. in Aerospace/Mechanical Engineering from the United States Military Academy at West Point, New York and a J.D. from Stanford Law School.

“We believe Mr. Shih’s successful track record, financial acumen and legal expertise will enhance our corporate oversight and governance policies, as well as help us evaluate potential acquisition targets” said Mr. Yang. “I look forward to working with Mr. Shih and the entire board as we execute our growth strategy.

About China Medicine Corporation

China Medicine Corporation is a developer, manufacturer and leading distributor in China of Western pharmaceuticals, traditional Chinese medicine products, other nutriceuticals, medical devices, and medical formulations. The Company also has its research and development force for certain products it manufactures through OEM arrangement and distributes. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.cmc621.com

Cautionary Statement

This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, the Company’s projections of LifeTech’s financial results for the 2009 year that just ended and for 2010 are materially different from the actual results, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, the approval of additional capital expenditures/acquisition projects by OEP and board of directors, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

Guangzhou, China, January 7, 2010 -- China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), primarily a leading distributor and a developer of Western pharmaceuticals, traditional Chinese medicines (“TCM”), and other nutriceuticals today announced that it has entered into a Stock Subscription Agreement for an equity private placement (the “Subscription Agreement”) with One Equity Partners ("OEP"), the global private equity investment arm of JPMorgan Chase & Co.

China Medicine is OEP's first investment in Greater China and reflects the firm's commitment to back aspirational management teams to accelerate the growth of their businesses.

Subject to certain closing conditions, OEP has agreed to purchase 4,000,000 of the Company’s common shares at $3.00 per share and 1,920,000 of the Company’s redeemable convertible preferred shares at $30 per share, for an aggregate purchase price of $69.6 million. Each redeemable convertible preferred share is initially convertible into ten common shares. At closing, the Company will receive $12 million in proceeds while the remaining $57.6 million in proceeds will be placed in escrow until released to fund additional capital expenditures and acquisition projects.

China Medicine expects to use the net proceeds of the financing for capital expenditures relating to its recent acquisition of LifeTech Pharmaceuticals Co. Ltd. (“LifeTech”), for working capital purposes, and for future expansion and/or acquisition projects subject to approval from OEP and the Company’s board of directors.

“We are delighted by OEP’s endorsement of our business strategy as we move higher in the pharmaceutical value chain by combining manufacturing capabilities with our nationwide distribution network and exciting new products,” said Mr. Senshan Yang, Chairman and CEO of China Medicine. “These include our proprietary recombinant Aflatoxin Detoxifizyme (rADTZ), a novel product for removing aflatoxins found in food and animal feed that we believe holds significant potential for future growth.” “Going forward, our strategy is to focus on developing and building brand recognition nationally to enhance the value of our enterprise.”

Ryan Shih, resident partner for OEP based in Hong Kong, said, “OEP is very impressed with China Medicine’s management team. With the LifeTech acquisition, the Company is transforming into a vertically-integrated distributor and developer of compelling products with attractive growth potential. The Company has established a leading position in China’s fast-growing pharmaceutical market, and we believe that the management team has the vision to capitalize on an extensive distribution network for medicines as well as develop innovative new products including new medicines and other products such as rADTZ.”

Under the Subscription Agreement, the Company has set a target of achieving $25 million in earnings before taxes, interests, depreciation and amortization (EBITDA) assuming that the Company completes certain other acquisitions in fiscal 2010. If such acquisitions are not completed during fiscal year 2010, then the Company will target a correspondingly lower EBITDA.

The common shares, including the common shares issuable upon the conversion of the redeemable convertible preferred shares that will be offered in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission (“SEC”) or through an applicable exemption from SEC registration requirements.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, any of the securities referred to in this news release in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About One Equity Partners

Established in 2001, One Equity Partners manages approximately $8 billion of investments and commitments for JPMorgan Chase & Co. in direct private equity transactions. One Equity Partners has invested in over 30 companies in a variety of industries including defense, chemicals, healthcare, technology and manufacturing. One Equity Partners’ investment professionals are located across North America, Europe and Asia, with offices in New York, Chicago, Menlo Park, Frankfurt and Hong Kong. Visit http://www.oneequity.com/ for more information.

About China Medicine Corporation

China Medicine Corporation is a developer and leading distributor of prescription and over- the-counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The Company also has its research and development force for certain products it manufactures through OEM arrangement and distributes. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.cmc621.com

Cautionary Statement

This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, the Company’s projections of LifeTech’s financial results for the 2009 year that just ended and for 2010 are materially different from the actual results, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

Guangzhou, China, October 30, 2009 -- China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), a developer and leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (“TCM”), nutritional and dietary supplements, and medical devices and medical formulations, today announced that through its wholly-owned subsidiary in China- Konzern Pharmaceuticals, it has signed an equity transfer agreement (the “Transfer Agreement”) to acquire 100% of equity interests in Sinoform Limited (“Sinoform”), a British Virgin Islands corporation, the sole shareholder of Guangzhou LifeTech Pharmaceuticals Co. Ltd. (“LifeTech”), a wholly-owned subsidiary of Sinoform. LifeTech is a developer, manufacturer and marketer of pharmaceuticals products and TCMs headquartered in Guangzhou, the People’s Republic of China (“PRC”).

Under the terms of the Transfer Agreement, China Medicine will acquire 100% of Sinoform’s equity in LifeTech for a cash payment of RMB 57 million (US $8.3 million; 1 RMB = $0.1464) and the assumption of RMB 89.8 million ($13.2 million) in debt. Upon closing of the acquisition, China Medicine will obtain LifeTech’s assets, appraised at RMB 174.3 million ($25.5 million), which include product licenses, permits, patents, land use rights, manufacturing facilities, state-of-the-art production equipment and a portfolio of 39 TCM and Western medicine products that treat a variety of illnesses, including two new products currently undergoing clinical trials. LifeTech top selling drug, Houerhuan Xiaoyan Capsules for the treatment of throat infections and acute laryngitis, is projected to account for 66% of LifeTech’s annual sales in 2009 and has a gross margin of 60-70%.

The acquisition is expected to close on or before December 31, 2009.  Pursuant to the Transfer Agreement, the Company will pay approximately $0.549 million of the cash purchase price and make a repayment of $7.3 million of LifeTech’s debt upon the execution of the Transfer Agreement and, upon approval of the transaction by the foreign trade bureau, the Company will pay an additional $3.7 million. The remaining balance of the purchase price will be made on or before June 30, 2010. The Company plans to finance the acquisition with existing cash, operating cash flow, and will explore opportunities for financing from commercial banks, if needed.

“This acquisition represents a strategic move in our evolution to a vertically integrated pharmaceutical company and we expect it will lay the foundation for a significant contribution to our profitability in the coming years,” said Mr. Senshan Yang, Chairman and CEO of China Medicine. “Specifically, the acquisition of LifeTech allows us to enhance our product line with high margin pharmaceuticals and improve our manufacturing capabilities for existing propriety products.”

Following the acquisition, based on the Company’s preliminary review of LifeTech’s unaudited historical financial statements and projections, the Company expects the acquisition to be accretive to earnings, generating revenues of between $10.0 million and $ 12.0 million and net profit margin of at least 40% in 2010.

About Guangzhou LifeTech Pharmaceuticals Co. Ltd.

Founded in 1992, Guangzhou LifeTech Pharmaceuticals Co. Ltd. is a developer and  manufacturer of pharmaceutical products with focus on natural-source vascular, anti-inflammatory, women’s health and other TCM and Western medicine products. For the past 10 years, the Company has invested more than $10 million in developing new drugs using extracts from all natural plants and herbs, and built up a solid product pipeline.  It currently sells its products in more than 10 provinces in China and has two products in final stages of clinical trials, including a TCM for the treatment of diabetes and an antibiotic intended for children. The Company’s manufacturing facility is GMP certified and has 170 employees.

About China Medicine Corporation

China Medicine Corporation is a developer and leading distributor of prescription and over-the-counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The Company also has its research and development force for certain products it manufactures through OEM arrangement and distributes. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.cmc621.com

Cautionary Statement

This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, the Company’s projections of Lifetech’s financial results in 2009 and 2010, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

Guangzhou, China – October 20, 2009 – China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (“TCM”), nutritional and dietary-supplements, medical devices, and medical formulations in the People’s Republic of China (“PRC”), announced today that one of its major products distributed by its fully owned subsidiary, Guangzhou Konzern Pharmaceutical Co., Ltd. (“Guangzhou Konzern”), Levocarnitine Dried Powder Injection (“Levocarnitine”), was registered with Ministry of Health of Pakistan on September 25, 2009. The registration number of Levocarnitine in Pakistan is 059054.

Guangzhou Konzern entered into a two year Distribution and Supply Agreement of Levocarnitine (“Agreement”) with RG Pharmaceutica (Pvt.) Ltd. (“RGP”), a Pakistani pharmaceutical distributor. The agreement stipulates that RGP will be responsible for the product registration, importation and marketing within the territory of Pakistan. Levocarnitine is used to treat coronary heart disease and acute myocardial infarction. Currently, there are no similar pharmaceutical products for Levocarnitine in Pakistan and the potential market for Levocarnitine in Pakistan is estimated at 2 million vials per year.

China Medicine expects to launch Levocarnitine in Pakistan in January 2010. The Company expects to ship approximately 100,000 vials of Levocarnitine within the first year of entering the market in Pakistan and estimates that gross margin for the product will not be less than 65%. Levocarnitine is manufactured by Guangzhou Lifetech Pharmaceutical Co., Ltd. in China (“Lifetech”). Lifetech is Guangzhou Konzern’s exclusive Original Equipment Manufacturer (“OEM”). Guangzhou Konzern distributed Levocarnitine in China in the years of 2008 and 2007, which generated revenues of $1,470,333 and $1,253,185 and gross profits of $570,074 and $473,006.

“We are excited to be able to export our OEM manufactured Levocarnitine powder injection to Pakistan, marking a major milestone for our company in entering this overseas pharmaceutical market,” commented Mr. Senshan Yang, Chairman and CEO of China Medicine. “In addition, we believe our strategic move to tap into the international pharmaceutical market overall will increase our profitability and maximize shareholder value.” 

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company that researches and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements. The Company distributes its products to more than 300 hospitals, 500 medicine companies, and 1,788 drug stores through wholesale distributors in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at www.cmc621.com.

Cautionary Statement

This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Guangzhou, China, August 31 2009 -- China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), a developer and leading distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced the appointment of Richard P. Wu as its new Chief Financial Officer, effective August 25, 2009. Mr. Wu replaces Ms. Huizhen Yu, who had served as Chief Financial Officer of China Medicine since February 2006. Ms. Yu now serves as Controller of the Company and its subsidiaries, including our wholly-owned operating subsidiary, Guangzhou Konzern Medicine Co., Ltd.. In addition, the Company also appointed Mr. Robert Lu to a newly created position of Finance Manager, which involves cash planning, internal and external reporting, tax planning and capital budgeting.

Richard P. Wu has over 14 years of experience in accounting and finance both in China and the U.S. including financial reporting, disclosure and regulatory compliance, financial planning, taxation, and debt and equity financing.  Mr. Wu also has a strong legal background as a practicing lawyer in China from 1987 to 1992. Prior to joining China Medicine, Mr. Wu was Chief Financial Officer and Executive Vice President of China Natural Gas, Inc. a NASDAQ Global-listed company, from 2008 to 2009. From January 2004 to May 2007 he was Chief Financial Officer and Corporate Senior Vice President of The AlliancePharm U.S. LLC’s China operations, where he had full finance and accounting responsibility for the sourcing and contract manufacturing business for active pharmaceutical ingredients and managed a finance and accounting team of over 100 people. From December 1999 to December 2003 he was Chief Financial Officer and Corporate EVP of MeetChina.com Inc.’s China business, an online cross-border ecommerce portal in China. From October 1997 to December 1999, he was senior director of Finance and VP Investment of the Paging Products Group in Greater China of Motorola Inc’s, a New York Stock Exchange-listed company. He also served as Investment Banking Associate and Vice President of Lehman Brothers Inc.’s New York and Hong Kong offices from 1995 to 1997. Mr. Wu graduated from the Wharton School, University of Pennsylvania in 1995 with an MBA degree in finance and accounting. He received a Master of Justice Administration degree from Indiana University in 1993, and a Master of Law degree from China University of Political Science and Law in 1987. Mr. Wu obtained a Bachelor of Arts degree from Zhengzhou University, China, in 1985 and is fluent in English and Mandarin.

Robert Lu has over six years of experience in finance and accounting and most recently served as international and regional tax manager for Huawei Technologies Co., Ltd, a global telecommunications provider based in Shenzhen, China. He holds a bachelor’s degree in accounting from the Harbin Institute of Technology and is fluent in both English and Mandarin.

“We are very happy to strengthen our financial management team with the appointment of Mr. Wu as Chief Financial Officer and Mr. Lu as Finance Manager,” stated Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. “Given Mr. Wu’s track record of success and extensive corporate accounting and financial experience, we believe he will make a significant contribution to our executive team as China Medicine continues to evolve as a public company.  Mr. Wu will also allow us to better support our relationship with the investment community as we seek to list our shares on a senior stock exchange.” Mr. Yang added, “We would also like to thank Ms. Yu for her continued dedication as she will now serve as Controller of China Medicine and our subsidiaries.”

About China Medicine Corporation

China Medicine Corporation is a developer and leading distributor of prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The Company also has its research and development force for certain products it manufactures through OEM arrangement and distributes. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.cmc621.com

Cautionary Statement

This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

Guangzhou, China, August xx, 2009 -- China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), a developer and a leading distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced its second quarter 2009 results.  

 Second Quarter 2009 Highlights:

§Revenues increased 29.4% from Q2 of 2008 to $15.1 million

§Gross profit decreased 15.1% from Q2 of 2008 to $3.5 million

§Operating income decreased 40.5% from Q2 of 2008 to $1.8 million

§Adjusted net income, which excluded a non-cash expense related to change in fair value of warrants for the second quarter of 2009, was $1.3 million, or $0.08 per diluted share

§Net income was $0.04 million, or $0.01 per diluted share

§Received third party feasibility report on rADTZ from the Feed Research Institute (FRI) of the Chinese Academy of Agricultural Sciences (CAAS)

§Commenced small scale-trial production and sales of rADTZ in June

§Obtained national distribution rights for Qinpi Jiegu tablets in China

§Obtained provincial distribution rights to Alendronate Sodium Tablets

§Received a loan of RMB 20 million (approximately U.S. $2.9 million) pursuant to the loan agreement with the Bank of China, Guangdong Branch

“We are pleased with our top line growth during the second quarter, during which we expanded regional and provincial distribution sales into rural areas and established trial sales of rADTZ, which has very high profit margins and promises to increase our profitability going forward. During the second quarter, our gross profit fell because of lower selling prices tied to severe price competition, an increase in sales of regional level distribution rights drugs, which have lower margins, and increased costs associated with promotional campaigns to increase sales. However, we believe that profitability will improve going forward since the second quarter is typically the slowest seasonally, and we have already seen an uptick in sales and profitability. As a result, we remain confident that our financial profile will improve and anticipate stronger sales in the second half of the year as we ramp up new proprietary products,” said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation.

“Our top-selling drugs for the quarter included Iopamidol by injection, which accounted for 13.7% of revenues and is used to help diagnose heart, brain, blood and nervous system disorders in X-rays or CT scans; Kelinao (Cinepazide Maleate Injection), which accounted for 6.7% of revenues and is used for the treatment of cardio-cerebral vascular diseases; and Hongjin Xiaojie capsules, which accounted for 5.4% of revenues are used to treat pain and for blood circulation. Combined gross margins for these products were 32.2 %. Collectively, our top three selling drugs accounted for approximately 25.8% of revenues,” said Mr. Yang.

Second Quarter 2009 Results

China Medicine’s total revenues in the second quarter were $15.1 million, an increase of 29.4% over the second quarter of 2008. This was attributable to an increase in the Company’s provincial and regional distribution sales as the Chinese government’s implementation of its rural health care reform policy presented new opportunities for expansion of the Company’s business in keeping with its strategic focus in 2008 to lay a solid foundation for a rural distribution network.

Product sales in the second quarter totaled $15.1 million and accounted for 100% of total net revenues. Sales of Western-style prescription products and over-the-counter products accounted for 73.9% of total revenues in the second quarter of 2009. Sales of TCM, prescription and over-the-counter products accounted for 22.8% of total revenues. Sales of dietary supplements and medical equipment accounted for 3.1% of revenues. Sales of rADTZ accounted for 0.2% of total revenue.

Gross profit in the second quarter of 2009 was $3.5 million, a decrease of 15.1% over the second quarter of 2008. Gross margin was 23.4% of total revenues for the second quarter, compared to 35.7% in the second quarter of 2008, and 27.5% in the first quarter of 2009. The decrease in gross profit was attributable to overall lower selling prices in the second quarter of 2009 due to increased sales of lower margin regional distribution products and an increase in the cost of some of our pharmaceutical products imposed by our suppliers. In addition, to respond to a trend of lower consumer spending tied to the global economic slowdown affecting the pharmaceutical industry, the Company increased its advertising efforts and spent more on promotional campaigns to increase sales.

Operating expenses in the second quarter of 2009 were $1.8 million, up 49.9% from $1.2 million in the second quarter of 2008.  The increase was due to higher selling, general and administrative expenses related to depreciation of assets and an increase in advertising fees, as well as higher transportation costs that resulted from increased sales during the quarter. Operating expenses represented 11.6% of total revenues in the second quarter of 2009, increase from 10.0% in the second quarter of 2008.

Operating income was $1.8 million in the second quarter of 2009, down 40.5% from $3.0 million in second quarter of 2008.  Operating margin was 11.8%, as compared to 25.7% during the same period a year ago.

The Company’s provision for income taxes was $570,014 for the three months ended June 30, 2009 compared to $572,176 for the comparable period of 2008. The decrease was due to the decrease in operating income. The decrease was subject to an effective income tax rate of 25% in 2009, versus a reduced rate of 16.5% in 2008, as tax exemptions enjoyed by the Company’s Konzern subsidiary ended in 2008.

Net income for the second quarter of 2009 was $0.04 million, or $0.003 per diluted share, which included a $1.2 million non-cash expense related to a change in the fair value of warrants, compared to $2.5 million or $0.16 per diluted share, in the second quarter of 2008. This is due to the adoption of a new accounting policy that became effective January 1, 2009, which requires changes in the fair value of warrants to be recognized in earnings each quarter. Excluding this expense, adjusted net income for the second quarter of 2009 was $1.3 million, or $0.08 per fully diluted share, which translates to a 49.1% decrease in net income for the second quarter of 2009 compared to the same period last year.

Six Month Results

 For the first half of 2009, revenues increased to $25.2 million, up 34.5% from $18.7 million in first half of 2008. Gross profit decreased 2.5% to $6.3 million in the first six months of 2009, versus $6.5 million in the first six month of 2008. Gross margin was 25.1% in the first half of 2008 compared to 34.6% during the first half of 2008. Operating income in the first half of 2009 decreased 19.4% to $3.5 million compared to $4.4 million in the first half 2008. Net income for the first six months of 2009 was $0.6 million or $0.04 per diluted share, compared to $3.6 million, or $0.23 per diluted share in the first half of 2008. Adjusted net income, excluding expenses related to fair value of warrants, was $2.6 million in first half 2009, or $0.17 per diluted share, which translates to a 29.6% decrease in net income for the first half of 2009 compared to the same period last year.

Financial Condition                   

As of June 30, 2009, China Medicine had $1.8 million in cash and cash equivalents. Working capital was approximately $33.0 million, up 1.4% from $32.5 million as of December 31, 2008.  Accounts receivable stood at $15.4 million as of June 30, 2009, down from $19.2 million as of December 31, 2008, reflecting increased customer collections. China Medicine Corporation Stockholders’ equity as of June 30, 2009 was $42.9 million compared to $42.8 million recorded as of December 31, 2008. For the six months ended June 30, 2009, cash from operating activities was $1.5 million. Cash flow used in investing activities was $2.6 million for the six months ended June 30, 2009, versus $0.6 million for the six months ended June 30, 2008. The increase is attributable to the purchase of know-how for a non-prescription medicine, Shiwuwei Syrup, which is used to enhance the respiratory system and increase the amount of hemoglobin in the blood.

Business Outlook 

 “We continue to make progress on executing our business plan as we enter second half of 2009 and are excited about the prospects for recombinant Alfatoxin Detoxifizyme (rADTZ), our innovative product that has the potential to detoxify alfatoxin (AFT), a potential cancer causing agent, in food and feed when used as an additive. We are pleased to have successfully commenced trial production and sales for our rADTZ, which have generated RMB 153,000 (approximately $22,400), with gross margin of approximately 65.4%. As we produce the product in greater scale and refine the technology used in the production process, we believe gross margin could be improved. We are very enthusiastic about the prospects for rADTZ and the demand for the product, and believe it will become one of the most important contributors to our growth in the coming years.

 “In terms of increasing our product portfolio to include products with exclusive national distribution rights, we added Qinpi Jiegu tablets to our portfolio in the second quarter, which are used to promote blood circulation to dissipate blood stasis and relieve pain. We also obtained exclusive provincial level distribution rights for Alendronate Sodium tablets used for treatment of osteoporosis. In keeping with our strategy, we plan to increase sales of pharmaceutical products with exclusive distribution rights, which have higher margins.  Overall, we are confident that our margins will improve going forward as sales for these products increase during the year,” said Mr. Yang.

“Recently, we have also received Quality Standard certification for our herbal tea series and expect to launch our self-branded herbal tea series into the market in August 2009. As we get further into the second half of 2009, we also expect to receive approval from the State Food and Drug Administration (SFDA) in October to start the production of our self-branded multivitamin series. We will be launching a comprehensive outdoor advertising campaign to promote our self-branded products, including our proprietary weight loss supplement—Bethin, during the second half of 2009. We remain confident that as we promote our brand image among Chinese consumers in Guangdong province, we will able to increase our profitability profile in the quarters ahead.”

“2009 is an important, transitional year for China Medicine as we set out to achieve our major goals of bringing the Company up to a higher platform. The increase of higher margin pharmaceutical products to our distribution pipeline and our plan to launch self-branded products will contribute to our bottom line growth. Furthermore, with our novel rADTZ product currently under review by the Department of Agriculture for product permit approval, we expect by the end of 2009, we will be able to commercialize this product and compete for a share of the $4.04 billion addressable market for rADTZ in China’s feed industry,” said Mr. Yang.

Conference Call

China Medicine will hold its second quarter conference call for all interested persons at 10:00 a.m. Eastern Time on Thursday, August 13, 2009, to discuss its results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time 866.800.8648. International callers should dial 617.614.2702. When prompted by the operator, mention conference passcode 175 848 10. If you are unable to participate in the call at its scheduled time, a replay will be available for 14 days starting on Thursday, May 13 at 12:00 p.m. Eastern Time. To access the replay, dial 888-286-8010 (international callers dial 617-801-6888, and enter the passcode 442 846 06.

About China Medicine Corporation

China Medicine Corporation is a developer and leading distributor of prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. China Medicine also has its research and development force for certain products it manufactures through OEM arrangement makes the distribution. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.cmc621.com

Use of Non-GAAP Financial Measures

GAAP results for second quarter 2009 include $1.2 million non cash expenses related to change in Company’s fair value of warrants. Because the expense is non-cash, and is not related to the Company’s operating results, the Company believes that the non-GAAP information is useful to supplement the Company's condensed consolidated financial statements. A reconciliation of the adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

Cautionary Statement

This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

-FINANCIAL TABLES FOLLOW-

Guangzhou, China – July 16, 2009 – China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (“TCM”), nutritional and dietary-supplements, medical devices, and medical formulations in the People’s Republic of China (“PRC”), announced today that it has received a third party feasibility report on recombinant Aflatoxin Detoxifizyme (rADTZ) from the Feed Research Institute (FRI) of the Chinese Academy of Agricultural Sciences (CAAS).

rADTZ is an innovative new product that has the potential to detoxify aflatoxin (AFT), a potential cancer causing agent, in food and feed when used as an additive. The report showed that experiments on baby chickens and piglets were positive where usage of the rADTZ enzyme in animal feed showed efficacy. Specifically, baby chickens and piglets experienced healthy growth in body and organ weight with rADTZ treated feed. In addition, the immunity system of animals in both working groups increased substantially, helping to decrease mortality rates. Based on the documented benefits of rADTZ, a separate study found that a breeder farm with the capacity of breeding 50 million chickens is expected to save up to 35 million RMB ($5.1 million) in costs through using rADTZ. 

“With this feasibility report, we have begun trial production of rADTZ and trial sales will follow very soon in China,” said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. “We are also eligible to apply for a product permit for rADTZ from the Ministry of Agriculture in China and expect to receive it in approximately six months. With the product permit, rADTZ can be sold nationally in China. We expect rADTZ to achieve net margins of 70% in 2009. We are remain very enthusiastic about the prospects of our novel product and believe rADTZ will become one of the most important contributors to China Medicine’s growth in the coming years,”

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company that discovers and develops medical formulations and distributes over 2,400 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements. The Company distributes its products to wholesale distributors in 28 provinces, more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.cmc621.com.

Guangzhou, China – July 8, 2009 – China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (“TCM”), nutritional and dietary-supplements, medical devices, and medical formulations in the People’s Republic of China (“PRC”), announced today that it has received a RMB 20 million (approximately U.S. $2.9 million) loan from the Bank of China, Guangdong branch. The term of the loan is one year with an interest rate of 5%.

Due to an award the Company received for being chosen as one of the ''Best 1000 Small & Medium Enterprises (SME)'' in Guangdong province, China Medicine enjoys the 5% interest rate payment reimbursable by both the municipal and provincial government in Guangdong province. The Company will use the loan to increase its current funds.

“We are very pleased to receive this loan and believe that such loan will facilitate our business expansion and increase our working capital,” said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation.

 About China Medicine Corporation

 China Medicine Corporation is a leading pharmaceutical company that discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements. The Company distributes its products to wholesale distributors in 28 provinces, more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.cmc621.com.

Guangzhou, China, June 4, 2009 -- China Medicine Corporation (OTCBB: CHME; “China Medicine” or “the Company”), a developer and leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines, nutritional and dietary-supplements, medical devices, and medical formulations in the People’s Republic of China (PRC), today announced it has signed a six-year agreement with Beijing Yushengtang Pharmaceutical Company Ltd. (“Yushengtang”) for national exclusive rights to distribute Qinpi Jiegu tablets in China.

Qinpi Jiegu tablets are used to promote blood circulation in order to dissipate blood stasis and relieve pain. They are also widely used to treat sprains and fractured bones and to relieve pain associated with these conditions.

“We are delighted to cooperate with Yushengtang, which was established in 1608. Yushengtang has a long history of R&D and marketing biopharmaceutical products, health food and food supplements etc. With our extensive distribution network covering 28 provinces in China, and our 20-year history distributing and developing pharmaceutical products, we believe our cooperation with Yushengtang will be mutually beneficial. The addition of Qinpi Jiegu tablets, and Nianlianping earlier this year, enabled us to achieve our goal of obtaining two new provincial/national distribution rights products to our portfolio. We will continue with our effort to increase our distributorship of pharmaceutical products with provincial/national distribution rights,” said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation.

 About China Medicine Corporation

China Medicine Corporation is a developer and leading distributor of prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. China Medicine also has its research and development force for certain products it manufactures through OEM arrangement makes the distribution. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.cmc621.com

 Cautionary Statement

 This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Guangzhou Konzern Pharmaceutical today announced that its Senior Professor, Mr. Jin Kui Xie has developed a prescription Traditional Chinese Medicine to prevent H1N1 flu. To view this prescription, please click here.

The prescription is for reference only.

China Medicine was granted the “Most Advanced Enterprise 2006--2008” Award by the Guangzhou Municipal government and the Communist Party Guangzhou Committee.

Based on China Medicine’s focus on the excellence of product, politics, spiritual and ecology in the pass three years, the Company was awarded the “Most Advanced Enterprise” by the Guangzhou Municipal government and Communist Party Guangzhou Committee in conjunction with the celebration of the International Labor Day recognizing role model enterprises and most advanced enterprises in Guangzhou for their positive contribution to the city. 

“We are honored to receive the award and will continue to strive to achieve best performance. We will also fully implement the central government’s “Pearl River Delta Reform and Development Program” that encourages humanity, continuity, harmonistic and growth. We are encouraging all of our employees to collaborate and work together during this difficult time. We are confidence that we can overcome the global financial crisis and achieve growth in this challenging environment.” said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation.

April 6th—China unveiled its blueprint for health care reform for the next decade detailing plans to fix the ailing medical system and ensure fair and affordable care for all 1.3 billion citizens.

In the new medical reform plan, the government has proposed to put medical technology innovation as one of the most important national technology development projects. The new plan encourages technology progress on China’s medical system, encourage proprietary technology innovation; increase R&D effort on key diseases treatment and prevention; promote R&D to combine TCM and Western medicine technology. This is China’s most comprehensive health care reformation since China’s reform and its opening up 30 years ago, In addition, the plan also outlines the roles of the government and enterprises in terms of addressing the country’s social benefit and healthcare issues. In the next three years, the Chinese government is committed to build approximately 2,000 county-level hospitals. The healthcare reform will cover 34,000 town-level clinics, 695,000 village health care centers, 3,700 city-level health care centers and 11,000 community service centers. All the above mentioned will provide excellent growth opportunities to China’s healthcare and pharmaceutical industry.

“The Chinese government’s plan to focus on innovation in the medical and healthcare industry in China matches our long-term growth strategy, In 2007, we made great strides in executing our business strategy and were one of the first movers in setting up our sales network in rural and municipal regions of Guangdong Province, We see this as an excellent opportunity for our Company to excel as one of the leading pharmaceutical developer in the new future.” concluded Mr. Senshan Yang, Chairman and CEO of China Medicine.

Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation, sees big opportunities in the medical industry as a result of recent statements by China Health Minister Chen Zhu to journalists at the National People’s Congress (NPC) and the Chinese People’s Political Consultative Conference (CPPCC).

"The new medical system reforms will startup immediately after NPC and CPPCC,” Chen Zhu said to the journalists during the NPC and CPPCC.* In addition, premier Wen Jiabao in his government work report said that China’s central and local government will spend 850 billion yuan in the next three years on wide-reaching health care reform. 

The impact of the new health care reform on China’s pharmaceutical industry is mainly in two areas: medical care and drug regulation. According to the new plan, 90% of urban and rural residents will be covered under the health care system by 2020. By then, there will be 1.28 billion Chinese enjoying benefits from the new system. It is also estimated that, with the medical care system improving continuously, the drug consumption will reach 200 billion yuan by year 2020, which represents approximately 40% of China’s pharmaceutical industry.

The health care reform will encourage pharmaceutical companies and related enterprises to conduct research and development on new drugs and will also raise the GSP standard on drug quality control and eliminate unqualified pharmaceutical entities. It is estimated within next three years, one third of pharmaceutical manufacturers and half of all drugs distributors in China will be eliminated. The pharmaceutical market will be more centralized, consisting of primarily of higher profile enterprises.

"The reform will be a big challenge for us, but we also see it as a great opportunity going forward," said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. “In the global economic downturn, China’s plan to invest 850 billion in health care reform will bring new life into many areas of the industry. There is little doubt that in three years, China’s pharmaceutical industry will get a big boost as a result."

"In order to take advantage of this opportunity, we are taking three specific steps. First, we are encouraging all of employees to collaborate and work together during this difficult time; Second, we will pay more attention to quality control everywhere across the organization; and third, we will restructure our management and executive team while also recruiting more talented people to prepare for the next coming upturn,” said Mr. Yang.

*source: People’s Daily Online

China Medicine Corporation will hold a Board Meeting in Guangzhou on March 12-13. During the session, Directors will visit warehouse and R&D facilities and have a discussion on how to retain and develop the company in this financial crisis atmosphere, and the performance of FY2008and plan for FY2009.

GUANGZHOU, China, Feb.26, 2009, -- China Medicine Corporation (OTC Bulletin Board: CHME; “China Medicine” or “the Company”), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (“TCM”), nutritional and dietary supplements, medical devices, and medical formulations in the People's Republic of China (“PRC”), through its wholly-owned U.S subsidiary, Konzern U.S Holding Corporation, announced today that it will participate in the 2009 Natural Products Expo West tradeshow, where it will showcase its weight loss product called ‘BeThin.’

The tradeshow will be held from March 5th to March 8th at the Anaheim Convention Center in California. It is the largest natural and organic products trade show in the world, and is expected to attract more than 50,000 attendees and feature more than 3,000 exhibits this year.

China Medicine’s proprietary weight loss product, BeThin, is a food supplement that is designed to promote and adjust fat metabolism, reduce the storage of fat in the body, and prolong endurance during physical exercise. In addition, the product is free from caffeine and ephedrine. The Company has filed and obtained the necessary documentation to launch the new product in the United States.

“We are looking forward to participating in the Natural Products Expo in the U.S. for a second time,” said Senshan Yang, Chairman and CEO of China Medicine. “Last October, we participated in the Natural Products Expo East tradeshow in Boston with favorable results, and as a result we are now cooperating with a supermarket chain to access the market for supplements in New York. We are confident that frequent exposure to BeThin at trade shows will lead to more market visibility and positive results.” 

The Company will be exhibiting its product in booth #1268. For more information on the tradeshow, please click www.expowest.com

Guangzhou China, July 14 -- China Medicine Corporation (OTC Bulletin Board: CHME; “China Medicine” or “the Company”), a leading distributor and developer of ethical and over-the-counter drugs, traditional Chinese medicines (TCMs), nutritional and dietary supplements, medical devices, and medical formulations in the People’s Republic of China (PRC), today announced that BeThin tablets—an original food supplement for fat and weight reduction, researched and developed by China Medicine Corporation ,will be for trial sale in the U.S..

BeThin tablets,which decrease lipid and adjust blood sugar level, have significant effects on obesitypatients with hypertension, hyperlipemia and diabetes, for both men and women, of batch production in Hongkong,and will be shipped to Houston,U.S. for trial sale on July,16,2008.

“As the preparatory work for research and development of BeThin went smoothly, I am confident that we will succeed in trial sale of the U.S. market,which helps to expand our shares in the international market and reach our goal to be an international enterprise!We wish BeThin can provide a healthy way to both men and women to BeThin. ” said Mr. Senshan Yang, Chairman and CEO of China Medicine.

GUANGZHOU, China, Jan. 5  -- China Medicine Corporation (OTC Bulletin Board: CHME ; "China Medicine" or "the Company"), a leading developer and distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, medical devices and medical formulations, announced today that it has renewed its contract with CCG Investor Relations for a primary term of one year commencing on January 1, 2009.

"After one year of service, we are happy to renew our contract and have CCG Investor Relations continue to design and execute our investor relations campaign," said Mr. Senshan Yang, Chief Executive Officer of China Medicine. "We are looking forward to utilizing CCG's full set of services to further raise our visibility in the investment community and support the rollout of recombinant Aflatoxin Detoxifizyme (rADTZ), our innovative product that has the potential to detoxify aflatoxin (AFT), a potential cancer causing agent, in food and feed."

China Medicine operates through its 100%-owned subsidiary, Guangzhou Konzern Pharmaceutical Company Ltd. ("Konzern"). In addition to maintaining its status as a leading distributor of pharmaceuticals in China, the Company has transformed itself into an innovative developer of Chinese pharmaceuticals and proprietary formulas. After the success of a reverse merger of Konzern into a public shell company in 2006, the Company ventured into research and development by establishing Guangzhou Co-win Bioengineering Co., Ltd. with Guangzhou Ji'nan Science & Technology Industrial Group and Mr. Dongsheng Yao, in which the Company, through Konzern, owns 70% equity interest. The rADTZ project has received a government grant and will continue to receive financial support from the government as one of "863" key projects starting commercialization after more than ten years of research and incubation.

"The harmful threat of aflatoxins presents an opportunity for China Medicine to increase the quality and standard of animal feed and human food," commented Crocker Coulson, President of CCG Investor Relations. "We intend to develop a well-orchestrated investor relations program to enhance China Medicine's profile in the investment community and will also assist the Company in educating investors about its new product strategy and line of innovative products."

Guangzhou, China – Dec. 15, 2008 -- China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), a leading developer and distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, medical devices and medical formulations, announced it received approval from the Guangdong Food & Drug Administration to distribute dental equipment and instruments, including brushes and drill bits, as well as oral surgery equipment, including scalpels, scissors, and forceps, in Guangdong Province . 

The approval was based on China Medicine meeting the requirements for storage space and the number of qualified professionals at the Company who can provide proper after-sales service. The domestic dental equipment industry in China is still in its early stages; however, with strong economic growth and increased personal income and improved living standards in China, there is now a growing awareness and demand for oral health care. As a result, the number of dental hospitals and clinics in China has risen. This has led to increased demand for dental equipment since new hospitals have to be outfitted with basic equipment to support the growth in dental health services. The Company believes that as demand for dental services continues to grow, the dental market in China will require higher-end equipment and products, which will bring more and more companies into the market and provide greater distribution opportunities.

"We are excited to have received approval from the Guangdong Food & Drug Administration to distribute this category of medical devices – dental equipment and instruments for oral surgery – which is a very important addition to our existing product portfolio,” said Mr. Senshan Yang, Chief Executive Officer of China Medicine Corporation.  “We believe that the market for dental equipment and surgical tools represents a major growth area in China as the demand for modern dental services continues to grow. We will distribute these new products through our existing distribution network starting December 2008, which we believe can achieve potential sales of more than 1.0 million dollars in 2009 based on several contracts that we have recently signed."

Guangzhou, China – December. 1, 2008 -- China Medicine Corporation (OTC BB: CHME) (“China Medicine” or “the Company”), a leading developer and distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations today announced that the Company was awarded GSP (Good Supply Practice for Pharmaceutical Products) certification from the Guangdong Food and Drug Administration (Guangdong FDA).

The GSP certification is given to pharmaceutical distributors that meet with the designated quality control systems required by the Guangdong FDA, which evaluates the management of employees, facility, inventory, sales and distribution systems, as well as product management systems. A stringent quality control system is required by the Chinese government to protect the integrity of the pharmaceutical industry in China as distributors are mandated to be GSP certified in order to engage in the pharmaceutical distribution business in China.

In conjunction with China Medicine’s success in obtaining the GSP certification, the Company will also be considered by the Guangdong FDA to include dentistry medical devices and instruments, peptide praeparatum and protein anabolica in its distribution product offering. The Company expects to receive the official approval in approximately 7 days for the aforementioned products.

"We are honored to have received the GSP certification and we will continue to promote and improve our quality control system to ensure the safety of the pharmaceutical products we distribute to the public,” said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. “Recently, we moved our warehouse to one that is double the size of the previous warehouse and is well furnished with state-of-the-art equipment, which includes a refrigeration storage facility. We are confident that our continuous commitment to high-standard quality control systems will further solidify our position as a leading developer and distributor of pharmaceutical products in China."